Literature DB >> 7933192

Prostatic UroLume Wallstent for urinary retention due to advanced prostate cancer: a 1-year followup study.

G Guazzoni1, F Montorsi, F Bergamaschi, P Consonni, P Rigatti.   

Abstract

We attempt to clarify the long-term clinical reliability of the prostatic UroLume Wallstent in the treatment of urinary retention due to advanced prostate cancer. The stent was placed in 11 stage D prostate cancer patients at high surgical risk and with urinary retention unrelieved by total androgen blockade. At preoperative urethroscopy, the bladder neck and verumontanum were clearly visible and not massively infiltrated by tumor. All patients voided spontaneously at the end of the procedure. At 1 year maximum flow nomograms demonstrated the definite relief of bladder outlet obstruction and of related symptoms in the 10 cases evaluated. As expected, the stent had no evident effect on the natural history of prostate cancer. There were no major complications. Bladder outlet obstruction due to advanced prostate cancer and unrelieved by conventional medical therapy can be treated safely and effectively by the prostatic UroLume Wallstent.

Entities:  

Mesh:

Year:  1994        PMID: 7933192     DOI: 10.1016/s0022-5347(17)32462-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  [Treatment of specific complications of locally advanced prostate cancer].

Authors:  F C von Rundstedt; A S Brandt; D Lazica; M J Mathers; S Roth
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

Review 2.  Managing the local complications of locally advanced prostate cancer.

Authors:  Jason W Anast; Gerald L Andriole; Robert L Grubb
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 3.  Urethral stents in benign prostate hyperplasia.

Authors:  Robert F Donnell
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

Review 4.  Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients.

Authors:  J S Lam; M A Volpe; S A Kaplan
Journal:  Curr Urol Rep       Date:  2001-08       Impact factor: 2.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.